Hemann MT - Search Results

1

Exploiting synthetic lethal interactions for targeted cancer therapy.

Reinhardt HC, Jiang H, Hemann MT, Yaffe MB. Reinhardt HC, et al. Among authors: hemann mt. Cell Cycle. 2009 Oct 1;8(19):3112-9. doi: 10.4161/cc.8.19.9626. Cell Cycle. 2009. PMID: 19755856 Free PMC article. Review.

2

The combined status of ATM and p53 link tumor development with therapeutic response.

Jiang H, Reinhardt HC, Bartkova J, Tommiska J, Blomqvist C, Nevanlinna H, Bartek J, Yaffe MB, Hemann MT. Jiang H, et al. Among authors: hemann mt. Genes Dev. 2009 Aug 15;23(16):1895-909. doi: 10.1101/gad.1815309. Epub 2009 Jul 16. Genes Dev. 2009. PMID: 19608766 Free PMC article.

3

A mammalian functional-genetic approach to characterizing cancer therapeutics.

Jiang H, Pritchard JR, Williams RT, Lauffenburger DA, Hemann MT. Jiang H, et al. Among authors: hemann mt. Nat Chem Biol. 2011 Feb;7(2):92-100. doi: 10.1038/nchembio.503. Epub 2010 Dec 26. Nat Chem Biol. 2011. PMID: 21186347 Free PMC article.

4

Bcl-2 family genetic profiling reveals microenvironment-specific determinants of chemotherapeutic response.

Pritchard JR, Gilbert LA, Meacham CE, Ricks JL, Jiang H, Lauffenburger DA, Hemann MT. Pritchard JR, et al. Among authors: hemann mt. Cancer Res. 2011 Sep 1;71(17):5850-8. doi: 10.1158/0008-5472.CAN-11-1014. Epub 2011 Jul 22. Cancer Res. 2011. PMID: 21784872 Free PMC article.

5

From breaking bad to worse: exploiting homologous DNA repair deficiency in cancer.

Hemann MT. Hemann MT. Cancer Discov. 2014 May;4(5):516-8. doi: 10.1158/2159-8290.CD-14-0316. Cancer Discov. 2014. PMID: 24795010 Free PMC article.

6

A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency.

Liu C, Ding H, Li X, Pallasch CP, Hong L, Guo D, Chen Y, Wang D, Wang W, Wang Y, Hemann MT, Jiang H. Liu C, et al. Among authors: hemann mt. EMBO Mol Med. 2015 Apr;7(4):438-49. doi: 10.15252/emmm.201404580. EMBO Mol Med. 2015. PMID: 25759362 Free PMC article.

7

A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to Chemotherapy.

Cannell IG, Merrick KA, Morandell S, Zhu CQ, Braun CJ, Grant RA, Cameron ER, Tsao MS, Hemann MT, Yaffe MB. Cannell IG, et al. Among authors: hemann mt. Cancer Cell. 2015 Nov 9;28(5):623-637. doi: 10.1016/j.ccell.2015.09.009. Cancer Cell. 2015. PMID: 26602816 Free PMC article.

8

Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution.

Zhao B, Sedlak JC, Srinivas R, Creixell P, Pritchard JR, Tidor B, Lauffenburger DA, Hemann MT. Zhao B, et al. Among authors: hemann mt. Cell. 2016 Mar 24;165(1):234-246. doi: 10.1016/j.cell.2016.01.045. Epub 2016 Feb 25. Cell. 2016. PMID: 26924578 Free PMC article.

9

A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to Chemotherapy.

Cannell IG, Merrick KA, Morandell S, Zhu CQ, Braun CJ, Grant RA, Cameron ER, Tsao MS, Hemann MT, Yaffe MB. Cannell IG, et al. Among authors: hemann mt. Cancer Cell. 2015 Dec 14;28(6):831. doi: 10.1016/j.ccell.2015.11.003. Epub 2015 Dec 14. Cancer Cell. 2015. PMID: 28843280 Free article. No abstract available.

10

Coordinated Splicing of Regulatory Detained Introns within Oncogenic Transcripts Creates an Exploitable Vulnerability in Malignant Glioma.

Braun CJ, Stanciu M, Boutz PL, Patterson JC, Calligaris D, Higuchi F, Neupane R, Fenoglio S, Cahill DP, Wakimoto H, Agar NYR, Yaffe MB, Sharp PA, Hemann MT, Lees JA. Braun CJ, et al. Among authors: hemann mt. Cancer Cell. 2017 Oct 9;32(4):411-426.e11. doi: 10.1016/j.ccell.2017.08.018. Epub 2017 Sep 28. Cancer Cell. 2017. PMID: 28966034 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

123 results

Search Page